Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia

NCT01939548 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01939548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01939548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2013
Completion date
October 31, 2014
Enrollment
240 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia